- Immunogenicity Crystal Ball: Integrating In Silico and Experimental Strategies for Predictive Immunogenicity Risk Assessment
-
Hemisfair Ballroom C3‚ Convention Center
Chair: Falgun Shah, Merck & Co. Inc.
Co-Chair: Laurent Melherbe, Eli Lily and Company
Primary Endorser: Drug Discovery Toxicology Specialty Section
Endorser(s): Immunotoxicology Specialty Section
Endorser(s): Computational Toxicology Specialty Section
Immunogenicity remains a major challenge in the development of biologics, including monoclonal antibodies, engineered proteins, and peptide therapeutics, because risk is influenced by product-related attributes, patient-specific factors, and the complex interplay of innate and adaptive immune responses. Despite substantial progress in the field, immunogenicity risk is still often identified late in development, when mitigation options are more limited and program impact is greater. At the same time, evolving regulatory expectations, including growing emphasis on New Approach Methodologies (NAMs) and integrated approaches for testing and assessment frameworks, are accelerating interest in human-relevant, non-animal strategies for earlier immunogenicity risk assessment. This session will examine how experimental and computational approaches can be combined to create a more predictive and mechanistically informed immunogenicity assessment paradigm. It will address how current tools for immunogenicity prediction can be integrated into a fit-for-purpose, end-to-end risk assessment framework that supports candidate selection, molecule optimization, and development-stage decision-making. By bringing together advances in assay platforms, computational prediction, and data standardization, this session will highlight immunogenicity as a high-value use case for NAM-enabled toxicology. The first speaker will focus on the current in vitro and ex vivo landscape, including assay platforms, harmonization, benchmarking, and translation into decision-making. The second speaker will focus on integrating in silico and in vitro immunogenicity assessments to improve predictive capability through statistical and mechanistic modeling. The third speaker will focus on the Immunogenicity Database Collaborative and the role of standardized, publicly available clinical immunogenicity data in strengthening computational approaches. The fourth speaker will focus on human-relevant in silico and cell-based assays for understanding immune-mediated toxicities and supporting clinical development decisions aligned with regulatory NAM strategy. Attendees will gain practical insights into how mechanistic assay platforms, computational prediction tools, and harmonized immunogenicity datasets can be combined into a practical, NAM-aligned framework for earlier and more informed immunogenicity risk assessment.Session and Activity Type
Enter Note
Go to previous page in this tab
Event
